ライフサイエンスコーパス: persistent atrial fibrillation

1 ter within the atrium of N=34 patients (n=24 persistent atrial fibrillation).

2 acoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation).

3 dergoing pulmonary vein antrum isolation for persistent atrial fibrillation.

4 ysiologically relevant heart rate control in persistent atrial fibrillation.

5 ardial stroma of patients with long-standing persistent atrial fibrillation.

6 atrial fibrillation and alter progression to persistent atrial fibrillation.

7 mong patients with symptomatic paroxysmal or persistent atrial fibrillation.

8 nefits of catheter ablation in patients with persistent atrial fibrillation.

9 61-71) years, 33.5% were women, and 52% had persistent atrial fibrillation.

10 custom mapping system to treat paroxysmal or persistent atrial fibrillation.

11 nary vein isolation+/-additional lesions for persistent atrial fibrillation.

12 atients with paroxysmal or non-long-standing persistent atrial fibrillation.

13 atients with paroxysmal or non-long-standing persistent atrial fibrillation.

14 rhythm in patients with both paroxysmal and persistent atrial fibrillation.

15 he treatment of persistent and long-standing persistent atrial fibrillation.

16 cardia, as well as an important substrate of persistent atrial fibrillation.

17 ients underwent pulmonary vein isolation for persistent atrial fibrillation.

18 major pathophysiological mechanism in human persistent atrial fibrillation.

19 ure, coronary disease, renal impairment, and persistent atrial fibrillation.

20 CTs reporting clinical outcomes after CA for persistent atrial fibrillation.

21 nd non-RCTs to assess the efficacy of CA for persistent atrial fibrillation.

22 million in European Union have paroxysmal or persistent atrial fibrillation.

23 went LA mapping before catheter ablation for persistent atrial fibrillation.

24 The primary end point was time to persistent atrial fibrillation.

25 ; 72%) or short-standing (<3-month duration) persistent atrial fibrillation (14 of 50 patients; 28%)

26 Of 71 patients with paroxysmal or persistent atrial fibrillation, 22 had progression to pe

27 ion (73%), primarily for paroxysmal (54%) or persistent atrial fibrillation (37%).

28 In 20 patients (68.9 5.8 years old; 60% persistent atrial fibrillation), 55 paired HP-SD and MP-

29 age, 61+/-10 years) with paroxysmal (550) or persistent atrial fibrillation (583).

30 mplication rates, and similarly low rates of persistent atrial fibrillation 60 days after onset.

31 ge, 68.8+/-8 years) with paroxysmal (32%) or persistent atrial fibrillation (68%) were randomized to

32 er (72 versus 74 years), more likely to have persistent atrial fibrillation (83.0% versus 77.6%), and

33 In persistent atrial fibrillation, a positive correlation w

34 ulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation [ADVANTAGE AF]; NCT054435

35 A) electric isolation is reported to improve persistent atrial fibrillation (AF) ablation outcomes.

36 performance in patients with paroxysmal and persistent atrial fibrillation (AF) and controls in sinu

37 Optimal treatment of patients with persistent atrial fibrillation (AF) and heart failure (H

38 r surgical ablation of de-novo long-standing persistent atrial fibrillation (AF) and its impact on AF

39 as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tach

40 servicing the increased energy demand during persistent atrial fibrillation (AF) and to ascertain whe

41 anisms responsible for perpetuation of human persistent atrial fibrillation (AF) are controversial an

42 Long-term success rates using ablation for persistent atrial fibrillation (AF) are disappointing an

43 Understanding and therapy of persistent atrial fibrillation (AF) are suboptimal partl

44 hypokalemia and female gender; by contrast, persistent atrial fibrillation (AF) at the time of drug

45 VI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with paroxy

46 d exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus r

47 ocalized drivers are proposed mechanisms for persistent atrial fibrillation (AF) from optical mapping

48 Catheter ablation of persistent atrial fibrillation (AF) has limited success.

49 d into catheter ablation (CA) strategies for persistent atrial fibrillation (AF) in an attempt to imp

50 pare catheter ablation with rate control for persistent atrial fibrillation (AF) in heart failure (HF

51 or to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with hea

52 The success rate of catheter ablation for persistent atrial fibrillation (AF) is still far from sa

53 Ablation of persistent atrial fibrillation (AF) remains a challenge.

54 ng-term successful outcomes with ablation of persistent atrial fibrillation (AF) remains a clinical a

55 catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeuti

56 isolation, the optimal ablation strategy for persistent atrial fibrillation (AF) remains poorly defin

57 The optimal ablation strategy for persistent atrial fibrillation (AF) remains unclear.

58 t atrial tachycardias (AT) in the context of persistent atrial fibrillation (AF) remains undetermined

59 lation (CA) for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the

60 ine 5-year efficacy of catheter ablation for persistent atrial fibrillation (AF) using AF termination

61 n is insufficient to treat all patients with persistent atrial fibrillation (AF), and effective adjun

62 f sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-des

63 In patients with recurrent persistent atrial fibrillation (AF), vulnerability to AF

64 y improve clinical outcomes in patients with persistent atrial fibrillation (AF).

65 isolation is the cornerstone of ablation for persistent atrial fibrillation (AF).

66 fibrosis are associated with maintenance of persistent atrial fibrillation (AF).

67 ablation is widely used for the treatment of persistent atrial fibrillation (AF).

68 underlying the transition from paroxysmal to persistent atrial fibrillation (AF).

69 o identify drivers in distinct categories of persistent atrial fibrillation (AF).

70 ging (MRI) and atrial electrograms (Egms) in persistent atrial fibrillation (AF).

71 (PVI) is less than optimal in patients with persistent atrial fibrillation (AF).

72 utcome of APVI in patients with long-lasting persistent atrial fibrillation (AF).

73 with a history of paroxysmal (40/66, 61%) or persistent atrial fibrillation and atrial tachyarrhythmi

74 reased in atrial appendages of patients with persistent atrial fibrillation and hearts of decorin nul

75 the left atrium is greater in patients with persistent atrial fibrillation and in those who do not r

76 In 30 patients with persistent atrial fibrillation and left ventricular ejec

77 Here, we expand those observations to persistent atrial fibrillation and severe heart failure.

78 between rotors and fibrosis in patients with persistent atrial fibrillation are mandatory and may inf

79 .9%) in the ablation group had an episode of persistent atrial fibrillation, as compared with 11 pati

80 eter ablation (CA) is commonly performed for persistent atrial fibrillation, but few high-quality ran

81 ng patients with persistent or long-standing persistent atrial fibrillation, but the risk of implanta

82 For patients with persistent atrial fibrillation, CA achieves significantl

83 Ablation of persistent atrial fibrillation can be challenging, often

84 Persistent atrial fibrillation developed in 110 patients

85 ODS AND Thirteen patients with long-standing persistent atrial fibrillation (duration, 12-72 months)

86 In patients with persistent atrial fibrillation, endocardial continuous h

87 PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation [FORWARD]; NCT00597220).

88 contrast, atrial appendages from patients in persistent atrial fibrillation had greater levels of ful

89 aroxysmal atrial fibrillation, patients with persistent atrial fibrillation had slightly larger diame

90 Catheter ablation of persistent atrial fibrillation has a lower success rate

91 ion Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure;

92 human model of advanced atrial substrate of persistent atrial fibrillation in heart failure.

93 The hazard ratio for development of persistent atrial fibrillation in patients with dual-cha

94 onization and moderately reduces the risk of persistent atrial fibrillation in patients with sinus-no

95 alcohol) per week and who had paroxysmal or persistent atrial fibrillation in sinus rhythm at baseli

96 Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated with limite

97 Electrical remodeling in human persistent atrial fibrillation is believed to result fro

98 term efficacy of catheter-based treatment of persistent atrial fibrillation is unsatisfactory.

99 ulsed Field Ablation System in Subjects with Persistent Atrial Fibrillation) is a prospective, single

100 Data regarding the first episode of persistent atrial fibrillation (lasting >=7 days or last

101 nt atrial fibrillation (PeAF), long-standing persistent atrial fibrillation (LPeAF), or paroxysmal at

102 icacy of catheter ablation for long-standing persistent atrial fibrillation (LS-AF).

103 uired intracardiac electrograms during human persistent atrial fibrillation mapping (n=16).

104 tients undergoing electric cardioversion for persistent atrial fibrillation, Mg infusion does not inc

105 ruction were studied in 5 systems: (1) human persistent atrial fibrillation (n=20), (2) tachypaced sh

106 n patients with persistent and long-standing persistent atrial fibrillation, no significant differenc

107 The primary endpoint was time to persistent atrial fibrillation or death.

108 ion was associated with a lower incidence of persistent atrial fibrillation or recurrent atrial tachy

109 d-stage HF patients, in patients with either persistent atrial fibrillation or sinus rhythm.

110 patient cohort included 55 paroxysmal and 21 persistent atrial fibrillation patients undergoing eithe

111 A total of 333 enrolled persistent atrial fibrillation patients underwent ablati

112 ulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF und

113 of paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PeAF) with survival, hea

114 n (PAF), 30 patients undergoing ablation for persistent atrial fibrillation (PeAF), and 30 patients u

115 ected "real-world" patients if sources drive persistent atrial fibrillation (PeAF), long-standing per

116 ness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions

117 ere are limited outcome data on PFA to treat persistent atrial fibrillation (PerAF).

118 rs and LGE signal intensity in patients with persistent atrial fibrillation (PERS) scheduled for abla

119 tional electroanatomical mapping systems for persistent atrial fibrillation (PersAF) ablation.

120 Various ablation strategies of persistent atrial fibrillation (PersAF) have had disappo

121 In patients with persistent atrial fibrillation (PersAF), catheter ablati

122 al myofibrillar degradation in patients with persistent atrial fibrillation (persAF), the intracellul

123 s in endocardial catheter ablation (ECA) for persistent atrial fibrillation (PersAF), undertreatment

124 (Pulsed Fields for Persistent Atrial Fibrillation [PersAFOne]; NCT04170621)

125 domains appropriately explain long-standing persistent atrial fibrillation physiology at its frequen

126 or exclusion criteria included long-standing persistent atrial fibrillation, prior left atrium ablati

127 Ablation for persistent atrial fibrillation (PsAF) has been performed

128 The underlying mechanisms sustaining human persistent atrial fibrillation (PsAF) is poorly understo

129 The optimal ablation strategy for persistent atrial fibrillation (PsAF) remains to be defi

130 xysmal atrial fibrillation or short-standing persistent atrial fibrillation, pulmonary vein (PV) isol

131 In human long-standing persistent atrial fibrillation, rotors potentially expla

132 Human patients with persistent atrial fibrillation show sixfold lower levels

133 a potential treatment option for recurrent, persistent atrial fibrillation, significant clinical eva

134 Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study, and the Stroke Pre

135 with symptomatic persistent or long-standing persistent atrial fibrillation, the outcomes of initial

136 ing, which could become an important goal in persistent atrial fibrillation therapy.

137 isolation improves outcomes in patients with persistent atrial fibrillation, there is no benefit of C

138 ts who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (26

139 tion may help with shared decision-making in persistent atrial fibrillation treatment.

140 in Patients With Persistent or Longstanding Persistent Atrial Fibrillation Undergoing Catheter Ablat

141 Eligible patients were adults with persistent atrial fibrillation undergoing planned cardio

142 venty patients (median age, 63.5 years) with persistent atrial fibrillation underwent epicardial thor

143 with symptomatic paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural

144 Patients with paroxysmal or persistent atrial fibrillation underwent pulmonary vein

145 Ten patients with symptomatic paroxysmal or persistent atrial fibrillation underwent single pulse IR

146 tact force-guided radiofrequency ablation of persistent atrial fibrillation was associated with a sig

147 tion at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation), we sought to assess, in

148 Thirty-eight patients with paroxysmal or persistent atrial fibrillation were treated in 6 centers

149 60 patients with persistent or long-standing persistent atrial fibrillation who required mitral-valve